Aliskiren is the first in a class of drugs called direct renin inhibitors. It is used for essential hypertension. While used for high blood pressure, other better-studied medications are typically recommended. Reference standards of Aliskiren Hemifumarate API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
Aliskiren Hemifumarate
Catalogue No.:PA 28 71000
CAS :
Molecular Formula : C32H55N3O8
Molecular Weight : 609.79
8-Hydroxy Aliskiren Hemifumarate
Catalogue No.:PA 28 71510
Molecular Formula : C32H55N3O9
Molecular Weight : 625.79
(2S,2'S,4S,4'S,5S,5'S,7S,7'S)-7,7'-(((Propane-1,3-diylbis(oxy))bis(4-methoxy-3,1-phenylene))bis(methylene))bis(5-amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-2-isopropyl-8-methylnonanamide)
Catalogue No.:PA 28 71520
Molecular Formula : C55H94N6O10
Molecular Weight : 999.37
(2S,4S,5S,7S)-5-Amino-N-(3-amino-2,2-dimethyl-3-oxopropyl)-4-hydroxy-7-(3-(3-hydroxypropoxy)-4-methoxybenzyl)-2-isopropyl-8-methylnonanamide
Catalogue No.:PA 28 71530
Molecular Formula : C29H51N3O6
Molecular Weight : 537.73
Aliskiren Carboxylic Acid
Catalogue No.:PA 28 71540
Molecular Formula : C30H52N2O7
Molecular Weight : 552.74
N-Boc-Aliskiren
Catalogue No.:PA 28 71550
Molecular Formula : C35H61N3O8
Molecular Weight : 651.87
Aliskiren Hemifumarate (SSSR Isomer) Impurity
Catalogue No.:PA 28 71560
Molecular Formula : C64H110N6O16
Molecular Weight : 1219.59
(3S,5S)-5-((1S,3S)-1-Amino-3-(4-methoxy-3-(3-methoxypropoxy)benzyl)-4-methylpentyl)-3-isopropyldihydrofuran-2(3H)-one
Catalogue No.:PA 28 71570
Molecular Formula : C25H41NO5
Molecular Weight : 435.6
(4S)-4-Benzyl-3-isovaleryloxazolidin-2-one
Catalogue No.:PA 28 0711000
Molecular Formula : C15H19NO3
Molecular Weight : 261.32
Aliskiren Hydrochloride
Catalogue No.:PA 28 71580
Molecular Formula : C30H54ClN3O6
Molecular Weight : 588.22
Aliskiren Hemifumarate Enantiomer (RRRR Isomer) Impurity
Catalogue No.:PA 28 0711001
Molecular Weight : 1219.61
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
